{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:12:26Z","timestamp":1775513546474,"version":"3.50.1"},"reference-count":111,"publisher":"European Respiratory Society (ERS)","issue":"160","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2020,11,17]]},"published-print":{"date-parts":[[2021,6,30]]},"abstract":"<jats:p>Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3\u2005years have been focused on the integration of immunotherapy into the combination treatment of a locally definitive therapy (surgery or radiotherapy) and chemotherapy. For concurrent chemoradiotherapy, consolidation therapy with durvalumab was established. Adjuvant targeted therapy has again gained increasing interest. In order to adapt treatment to the specific stage subgroup and its prognosis, fluorodeoxyglucose positron emission tomography\/computed tomography and pathological evaluation of the mediastinum are important. Tumours should be investigated for immunological features and driver mutations. Regarding toxicity, evaluation of pulmonary and cardiac function, as well as symptoms and quality of life, is of increasing importance. To improve the management and prognosis of this heterogeneous entity, clinical trials and registries should take these factors into account.<\/jats:p>","DOI":"10.1183\/16000617.0227-2020","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T14:33:46Z","timestamp":1620225226000},"page":"200227","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["New developments in locally advanced nonsmall cell lung cancer"],"prefix":"10.1183","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-6368","authenticated-orcid":false,"given":"Rudolf M.","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Flentje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"2024102403533394000_30.160.200227.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"2024102403533394000_30.160.200227.2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0024-2019"},{"key":"2024102403533394000_30.160.200227.3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403533394000_30.160.200227.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.4401"},{"key":"2024102403533394000_30.160.200227.5","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00159-2019"},{"key":"2024102403533394000_30.160.200227.6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024102403533394000_30.160.200227.7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2017.12.016","article-title":"A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer","volume":"117","author":"Sculier","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.19.02674","article-title":"Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024102403533394000_30.160.200227.9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","article-title":"Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III NSCLC","volume":"15","author":"Tan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024102403533394000_30.160.200227.10","doi-asserted-by":"crossref","first-page":"S2593","DOI":"10.21037\/jtd.2018.08.18","article-title":"Prehabilitation in thoracic surgery","volume":"10:","author":"Sanchez-Lorente","year":"2018","journal-title":"J Thorac Dis"},{"key":"2024102403533394000_30.160.200227.11","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1200\/JOP.19.00781","article-title":"Treatment decision drivers in stage III non-small-cell lung cancer: outcomes of a web-based survey of oncologists in the United States","volume":"16","author":"Cotarla","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2024102403533394000_30.160.200227.12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2478\/raon-2020-0026","article-title":"Care of patients with non-small-cell lung cancer stage III \u2013 the Central European real-world experience","volume":"54","author":"Zemanova","year":"2020","journal-title":"Radiol Oncol"},{"key":"2024102403533394000_30.160.200227.13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/EDBK_237839","article-title":"Updates in local-regionally advanced non\u2013small cell lung cancer","volume":"39","author":"Tsao","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2024102403533394000_30.160.200227.14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000500363","article-title":"Endobronchial ultrasound for the diagnosis of centrally located lung tumors: a systematic review and meta-analysis","volume":"99","author":"Kuijvenhoven","year":"2020","journal-title":"Respiration"},{"key":"2024102403533394000_30.160.200227.15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chest.2018.04.014","article-title":"Efficacy of endosonographic procedures in mediastinal re-staging of lung cancer after neoadjuvant therapy: a systematic review and diagnostic accuracy meta-analysis","volume":"154","author":"Muthu","year":"2018","journal-title":"Chest"},{"key":"2024102403533394000_30.160.200227.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00184308"},{"key":"2024102403533394000_30.160.200227.17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s10554-019-01590-0","article-title":"The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy","volume":"35","author":"Chen","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"2024102403533394000_30.160.200227.18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ultrasmedbio.2018.09.012","article-title":"Prognostic and added value of echocardiographic strain for prediction of adverse outcomes in patients with locally advanced non-small cell lung cancer after radiotherapy","volume":"45","author":"Chen","year":"2019","journal-title":"Ultrasound Med Biol"},{"key":"2024102403533394000_30.160.200227.19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3389\/fonc.2019.01511","article-title":"Left ventricular systolic dysfunction is a possible independent risk factor of radiation pneumonitis in locally advanced lung cancer patients","volume":"9","author":"Cai","year":"2019","journal-title":"Front Oncol"},{"key":"2024102403533394000_30.160.200227.20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(18)30172-3","article-title":"Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy","volume":"6","author":"Rashdan","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102403533394000_30.160.200227.21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25894"},{"key":"2024102403533394000_30.160.200227.22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fonc.2020.00561","article-title":"Radiation recall pneumonitis induced by anti-PD-1 blockade: a case report and review of the literature","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"2024102403533394000_30.160.200227.23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.24","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cllc.2020.04.003","article-title":"A population-based study of immunotherapy-related toxicities in lung cancer","volume":"21","author":"Cathcart-Rake","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.001"},{"key":"2024102403533394000_30.160.200227.27","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13911"},{"key":"2024102403533394000_30.160.200227.28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2020.01.014","article-title":"Dose to highly functional ventilation zones improves prediction of radiation pneumonitis for proton and photon lung cancer radiotherapy","volume":"107","author":"O'Reilly","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024102403533394000_30.160.200227.29","doi-asserted-by":"crossref","first-page":"20190743","DOI":"10.1259\/bjr.20190743","article-title":"Image-guidance triggered adaptive replanning of radiation therapy for locally advanced lung cancer: an evaluation of cases requiring plan adaptation","volume":"93","author":"Appel","year":"2020","journal-title":"Br J Radiol"},{"key":"2024102403533394000_30.160.200227.30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00066-019-01518-6","article-title":"Image-based lung functional radiotherapy planning for non-small cell lung cancer","volume":"196","author":"Mounessi","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"2024102403533394000_30.160.200227.31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","article-title":"GILT \u2013 a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer","volume":"192","author":"Flentje","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"2024102403533394000_30.160.200227.32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024102403533394000_30.160.200227.33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12094-018-1949-6","article-title":"Effect of PET\/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer","volume":"21","author":"Ercelep","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"2024102403533394000_30.160.200227.34","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.cllc.2018.08.018","article-title":"Significance of (18)F-FDG PET parameters according to histologic subtype in the treatment outcome of stage III non-small-cell lung cancer undergoing definitive concurrent chemoradiotherapy","volume":"20","author":"Kim","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cllc.2019.07.004","article-title":"Predictive and prognostic role of metabolic response in patients with stage III NSCLC treated with neoadjuvant chemotherapy","volume":"21","author":"Castello","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.36","doi-asserted-by":"crossref","first-page":"e0222885","DOI":"10.1371\/journal.pone.0222885","article-title":"Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II\/III non-small cell lung cancer before (chemo-) radiation","volume":"14","author":"Ganem","year":"2019","journal-title":"PLoS One"},{"key":"2024102403533394000_30.160.200227.37","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2214\/AJR.19.21376","article-title":"Prognostic value of the volumetric parameters of dual-time-point (18)F-FDG PET\/CT in non-small cell lung cancer treated with definitive radiation therapy","volume":"213","author":"Okazaki","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"2024102403533394000_30.160.200227.38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/kjm2.12027","article-title":"Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-based 18F-FDG PET\/CT in stage III non-small cell lung cancer","volume":"35","author":"Chen","year":"2019","journal-title":"Kaohsiung J Med Sci"},{"key":"2024102403533394000_30.160.200227.39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00066-017-1229-3","article-title":"Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer","volume":"194","author":"Roengvoraphoj","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"2024102403533394000_30.160.200227.40","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00259-018-4063-7","article-title":"How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience","volume":"45","author":"Roengvoraphoj","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024102403533394000_30.160.200227.41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00259-018-4139-4","article-title":"Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients","volume":"46","author":"Arshad","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024102403533394000_30.160.200227.42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2018.12.005","article-title":"Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer","volume":"128","author":"Ono","year":"2019","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.06.023","article-title":"The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer","volume":"123","author":"Jao","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/14737140.2019.1621754","article-title":"The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"19","author":"Qin","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"2024102403533394000_30.160.200227.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4824"},{"key":"2024102403533394000_30.160.200227.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1816"},{"key":"2024102403533394000_30.160.200227.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30729-5"},{"key":"2024102403533394000_30.160.200227.48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.18.00131","article-title":"SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Pennell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024102403533394000_30.160.200227.49","doi-asserted-by":"crossref","unstructured":"Wu Y-L , Zhong W , Wang Q , et al. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation \u2013 Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. J Clin Oncol 2020; 38: 15_suppl, 9005-9005.","DOI":"10.1200\/JCO.2020.38.15_suppl.9005"},{"key":"2024102403533394000_30.160.200227.50","doi-asserted-by":"crossref","unstructured":"Herbst RS , Tsuboi M , John T , et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB\u2013IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA . J Clin Oncol 2020; 38: 18_suppl, LBA5-LBA5. doi:10.1200\/JCO.2020.38.18_suppl.LBA5","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA5"},{"key":"2024102403533394000_30.160.200227.51","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13191"},{"key":"2024102403533394000_30.160.200227.52","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024102403533394000_30.160.200227.53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.athoracsur.2017.08.052","article-title":"Induction cisplatin docetaxel followed by surgery and erlotinib in non-small cell lung cancer","volume":"105","author":"Cascone","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2024102403533394000_30.160.200227.54","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cllc.2018.08.017","article-title":"A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III non-small-cell lung cancer harboring EGFR mutations (WJOG6911L)","volume":"20","author":"Akamatsu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11912-019-0835-x","article-title":"Role of anti-EGFR targeted therapies in stage III locally advanced non-small cell lung cancer: give or not to give?","volume":"21","author":"Desai","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2024102403533394000_30.160.200227.56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/CCO.0000000000000497","article-title":"Immunotherapy in patients with early stage resectable nonsmall cell lung cancer","volume":"31","author":"Ghysen","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2024102403533394000_30.160.200227.57","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","article-title":"Current status of immune checkpoint inhibition in early-stage NSCLC","volume":"30","author":"Vansteenkiste","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403533394000_30.160.200227.58","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0713"},{"key":"2024102403533394000_30.160.200227.59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"2024102403533394000_30.160.200227.60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0970"},{"key":"2024102403533394000_30.160.200227.61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/1759-7714.12935","article-title":"Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma","volume":"10","author":"Nishihira","year":"2019","journal-title":"Thorac Cancer"},{"key":"2024102403533394000_30.160.200227.62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7150\/jca.21842","article-title":"Classifying non-small cell lung cancer by status of programmed cell death ligand 1 and tumor-infiltrating lymphocytes on tumor cells","volume":"9","author":"Cui","year":"2018","journal-title":"J Cancer"},{"key":"2024102403533394000_30.160.200227.63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.1963"},{"key":"2024102403533394000_30.160.200227.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078"},{"key":"2024102403533394000_30.160.200227.65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/tlcr.2019.08.04","article-title":"The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients","volume":"8","author":"Li","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2024102403533394000_30.160.200227.66","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2018.12.022","article-title":"Prognostic impact of tumor cell programmed death ligand 1 expression and immune cell infiltration in NSCLC","volume":"14","author":"Edlund","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024102403533394000_30.160.200227.67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/annonc\/mdx003","article-title":"PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer","volume":"28","author":"Tsao","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403533394000_30.160.200227.68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jtho.2018.09.006","article-title":"Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma","volume":"14","author":"Yu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024102403533394000_30.160.200227.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0398-5"},{"key":"2024102403533394000_30.160.200227.70","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JOP.18.00127","article-title":"Complete pathologic response when adding pembrolizumab to neoadjuvant chemotherapy in stage IIIA non\u2013small-cell lung cancer","volume":"14","author":"Hill","year":"2018","journal-title":"J Oncol Pract"},{"key":"2024102403533394000_30.160.200227.71","doi-asserted-by":"crossref","first-page":"abstr 8503","DOI":"10.1200\/JCO.2019.37.15_suppl.8503","article-title":"Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)","volume":"37","author":"Kwiatkowski","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024102403533394000_30.160.200227.72","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024102403533394000_30.160.200227.73","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jamaoncol.2018.7220","article-title":"Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG Oncology\/RTOG 0214 phase 3 randomized clinical trial","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024102403533394000_30.160.200227.74","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2017.77.5817","article-title":"Prophylactic cranial irradiation versus observation in radically treated stage III non\u2013small-cell lung cancer: a randomized phase III NVALT-11\/DLCRG-02 study","volume":"36","author":"De Ruysscher","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403533394000_30.160.200227.75","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/cam4.2937","article-title":"Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: a single-center, retrospective study","volume":"9","author":"Wei","year":"2020","journal-title":"Cancer Med"},{"key":"2024102403533394000_30.160.200227.76","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.athoracsur.2018.04.064","article-title":"Postoperative radiotherapy for surgically resected ypN2 non-small cell lung cancer","volume":"106","author":"Brandt","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2024102403533394000_30.160.200227.77","doi-asserted-by":"crossref","first-page":"718","DOI":"10.6004\/jnccn.2020.7537","article-title":"Effects of postoperative radiotherapy on survival of patients with stage IIIA resected non\u2013small cell lung cancer: analysis of the SEER database","volume":"18","author":"Gao","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2024102403533394000_30.160.200227.78","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/1759-7714.12920","article-title":"Quantitative severity of pulmonary emphysema as a prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer","volume":"10","author":"Lee","year":"2019","journal-title":"Thorac Cancer"},{"key":"2024102403533394000_30.160.200227.79","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2017.11.014","article-title":"Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy","volume":"115","author":"Isaka","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.80","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/03007995.2019.1623185","article-title":"Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer","volume":"35","author":"Govindan","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2024102403533394000_30.160.200227.81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12032-019-1249-1","article-title":"Real-world outcomes in patients with unresected stage III non-small cell lung cancer","volume":"36","author":"Ryan","year":"2019","journal-title":"Med Oncol"},{"key":"2024102403533394000_30.160.200227.82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12325-019-0876-4","article-title":"Unmet clinical need in the management of locally advanced unresectable lung cancer: treatment strategies to improve patient outcomes","volume":"36","author":"Rajappa","year":"2019","journal-title":"Adv Ther"},{"key":"2024102403533394000_30.160.200227.83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canrad.2019.09.007","article-title":"[Role of immunotherapy in locally advanced non-small cell lung cancer]","volume":"24","author":"Levy","year":"2020","journal-title":"Cancer Radiother"},{"key":"2024102403533394000_30.160.200227.84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2024102403533394000_30.160.200227.85","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403533394000_30.160.200227.86","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdy553","article-title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","volume":"30","author":"Peters","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403533394000_30.160.200227.87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2478\/raon-2018-0009","article-title":"Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy","volume":"52","author":"Vrankar","year":"2018","journal-title":"Radiol Oncol"},{"key":"2024102403533394000_30.160.200227.88","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jtho.2018.04.017","article-title":"PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections","volume":"13","author":"Munari","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403533394000_30.160.200227.89","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40273-019-00870-w","article-title":"Durvalumab for the treatment of locally advanced, unresectable, stage III non-small cell lung cancer: an evidence review group perspective of a NICE single technology appraisal","volume":"38","author":"Witlox","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2024102403533394000_30.160.200227.90","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2018.5449","article-title":"Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the US health care system","volume":"5","author":"Criss","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024102403533394000_30.160.200227.91","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","article-title":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","volume":"57","author":"Sakaguchi","year":"2019","journal-title":"Respir Investig"},{"key":"2024102403533394000_30.160.200227.92","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00280-019-03885-4","article-title":"Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients","volume":"84","author":"Hosoya","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl. 3","key":"2024102403533394000_30.160.200227.93","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.21037\/jtd.2018.01.109","article-title":"Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer","volume":"10:","author":"Yeh","year":"2018","journal-title":"J Thorac Dis"},{"key":"2024102403533394000_30.160.200227.94","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cllc.2019.06.009","article-title":"Prognostic variables associated with improved outcomes in patients with stage III NSCLC treated with chemoradiation followed by consolidation pembrolizumab: a subset analysis of a phase II study from the Hoosier Cancer Research Network LUN 14\u2013179","volume":"21","author":"Anouti","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.95","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.96","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.radonc.2018.05.017","article-title":"Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer","volume":"128","author":"Contreras","year":"2018","journal-title":"Radiother Oncol"},{"key":"2024102403533394000_30.160.200227.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.064"},{"key":"2024102403533394000_30.160.200227.98","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2019.07.027","article-title":"Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy","volume":"136","author":"Choe","year":"2019","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.99","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","article-title":"Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer","volume":"121","author":"Yoneda","year":"2019","journal-title":"Br J Cancer"},{"key":"2024102403533394000_30.160.200227.100","doi-asserted-by":"crossref","first-page":"e0204490","DOI":"10.1371\/journal.pone.0204490","article-title":"Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer","volume":"13","author":"Schernberg","year":"2018","journal-title":"PLoS One"},{"key":"2024102403533394000_30.160.200227.101","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2018.04.016","article-title":"Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer","volume":"121","author":"Topkan","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403533394000_30.160.200227.102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3857\/roj.2019.00220","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"37","author":"Park","year":"2019","journal-title":"Radiat Oncol J"},{"key":"2024102403533394000_30.160.200227.103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13014-019-1440-8","article-title":"Risk factors of grade \u22652 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer","volume":"14","author":"Sheng","year":"2019","journal-title":"Radiat Oncol"},{"key":"2024102403533394000_30.160.200227.104","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/1759-7714.13276","article-title":"Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer","volume":"11","author":"Grambozov","year":"2020","journal-title":"Thorac Cancer"},{"key":"2024102403533394000_30.160.200227.105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.radonc.2019.01.003","article-title":"Predicting radiation pneumonitis in locally advanced stage II-III non-small cell lung cancer using machine learning","volume":"133","author":"Luna","year":"2019","journal-title":"Radiother Oncol"},{"key":"2024102403533394000_30.160.200227.106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tlcr.2019.10.06","article-title":"Patient-reported outcome measures in definitive chemoradiation for non-small cell lung cancer","volume":"9","author":"Voong","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2024102403533394000_30.160.200227.107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.21037\/tlcr.2019.08.21","article-title":"Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer","volume":"8","author":"Vogel","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2024102403533394000_30.160.200227.108","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13701"},{"key":"2024102403533394000_30.160.200227.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.003"},{"key":"2024102403533394000_30.160.200227.110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2018.08.009","article-title":"Analysis of relapse events after definitive chemoradiotherapy in locally advanced non-small-cell lung cancer patients","volume":"20","author":"Grass","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024102403533394000_30.160.200227.111","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/COC.0000000000000235","article-title":"Prognostic factors as a function of disease-free interval after definitive (chemo)radiation for non-small cell lung cancer using conditional survival analysis","volume":"41","author":"Hong","year":"2018","journal-title":"Am J Clin Oncol"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0227-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:02:57Z","timestamp":1740373377000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0227-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":111,"journal-issue":{"issue":"160","published-online":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,6,30]]}},"alternative-id":["10.1183\/16000617.0227-2020"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0227-2020","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]}}}